In this regard, it has been demonstrated that MS disease progression can be inhibited by the use of IFN-β and vitamin D, which induces increased levels of LILRB4 on APCs during MS exacerbations [83]. The gene discussed is LILRB4; the disease is myeloid sarcoma.